JP2016525516A5 - - Google Patents

Download PDF

Info

Publication number
JP2016525516A5
JP2016525516A5 JP2016526515A JP2016526515A JP2016525516A5 JP 2016525516 A5 JP2016525516 A5 JP 2016525516A5 JP 2016526515 A JP2016526515 A JP 2016526515A JP 2016526515 A JP2016526515 A JP 2016526515A JP 2016525516 A5 JP2016525516 A5 JP 2016525516A5
Authority
JP
Japan
Prior art keywords
composition
mutation
cytokine
mutated
leptin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016526515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525516A (ja
JP6580037B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/064227 external-priority patent/WO2015007536A2/en
Publication of JP2016525516A publication Critical patent/JP2016525516A/ja
Publication of JP2016525516A5 publication Critical patent/JP2016525516A5/ja
Application granted granted Critical
Publication of JP6580037B2 publication Critical patent/JP6580037B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016526515A 2013-07-18 2014-07-03 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン Active JP6580037B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306034.3 2013-07-18
EP13306034 2013-07-18
PCT/EP2014/064227 WO2015007536A2 (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019154901A Division JP6853317B2 (ja) 2013-07-18 2019-08-27 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン

Publications (3)

Publication Number Publication Date
JP2016525516A JP2016525516A (ja) 2016-08-25
JP2016525516A5 true JP2016525516A5 (enExample) 2017-08-10
JP6580037B2 JP6580037B2 (ja) 2019-09-25

Family

ID=48906191

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016526515A Active JP6580037B2 (ja) 2013-07-18 2014-07-03 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン
JP2019154901A Active JP6853317B2 (ja) 2013-07-18 2019-08-27 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019154901A Active JP6853317B2 (ja) 2013-07-18 2019-08-27 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン

Country Status (14)

Country Link
US (3) US10640542B2 (enExample)
EP (2) EP3299466B1 (enExample)
JP (2) JP6580037B2 (enExample)
KR (1) KR102322510B1 (enExample)
CN (2) CN110835376B (enExample)
AU (2) AU2014292371B2 (enExample)
BR (1) BR112016001036B1 (enExample)
CA (1) CA2917937C (enExample)
DK (1) DK3299466T3 (enExample)
ES (2) ES2657060T3 (enExample)
IL (1) IL243451B (enExample)
MX (1) MX375441B (enExample)
SG (2) SG11201600163VA (enExample)
WO (1) WO2015007536A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
EP4276114A3 (en) 2016-03-07 2024-02-21 Vib Vzw Cd20 binding single domain antibodies
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
US11236141B2 (en) 2016-05-13 2022-02-01 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
JP7204643B2 (ja) 2016-10-24 2023-01-16 オリオニス バイオサイエンシズ ビーブイ 標的変異インターフェロン-ガンマおよびその使用
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Pd-1およびpd-l1結合物質
WO2019032661A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. CD8 LIAISON AGENTS
BR112020002706A2 (pt) 2017-08-09 2020-08-25 Orionis Biosciences Inc. agentes de ligação a clec9a e uso dos mesmos
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス, インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
CN112074267B (zh) 2018-02-05 2024-06-28 奥里尼斯生物科学公司股份有限公司 成纤维细胞结合剂及其用途
US12084497B2 (en) 2018-08-08 2024-09-10 Orionis Biosciences, Inc. SIRP1α targeted chimeric proteins and uses thereof
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ,インコーポレイテッド 治療用インターフェロンアルファ1タンパク質
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ,インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
US12351614B2 (en) 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes
US12544426B2 (en) 2019-06-19 2026-02-10 Orionis Biosciences, Inc. Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes
US20230293652A1 (en) * 2020-07-07 2023-09-21 Orionis Biosciences, Inc. Immunostimulatory adjuvants
PE20231175A1 (es) 2020-11-19 2023-08-01 Kalivir Immunotherapeutics Inc Inmunoterapia oncolitica por remodelacion del microambiente tumoral
IL316712B2 (en) * 2021-04-30 2025-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for modified mhc expression
US20240166706A1 (en) * 2022-11-21 2024-05-23 Wisconsin Alumni Research Foundation Synthetic il6-il1beta fusion cytokine for promoting t cell cytotoxic function, t cell proliferation, and tumoricidal activity

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3115318B2 (ja) * 1989-08-22 2000-12-04 イミュネックス・コーポレーション Gm―csf及びil―3を含む融合タンパク質
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
BR0013231A (pt) * 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
WO2002044394A2 (en) * 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
CA2693326A1 (en) 2006-08-02 2008-02-07 Mcgill University Gm-csf and il-15 fusokines and methods for modulation of the immune response
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
EP2173377B1 (en) 2007-06-26 2017-11-29 University of Miami Antibody-endostatin fusion protein and its variants
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
WO2010036918A2 (en) 2008-09-26 2010-04-01 University Of Massachusetts Intracellular dna receptor
CA2749558C (en) 2008-12-08 2019-01-15 Complix Nv Single-chain antiparallel coiled coil proteins
PE20120630A1 (es) 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
JP2013504539A (ja) 2009-09-10 2013-02-07 サイトス バイオテクノロジー アーゲー 糖尿病治療におけるインターロイキン1βムテイン・コンジュゲートの使用
CA2779512C (en) * 2009-11-02 2017-01-17 Leonard H. Rome Vault complexes for cytokine delivery
EP2515916B1 (en) * 2009-12-23 2016-03-09 Gradalis, Inc. Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
CN102958531A (zh) * 2010-04-22 2013-03-06 耶路撒冷希伯来大学伊森姆研究发展公司 高亲和力瘦蛋白和瘦蛋白拮抗剂
CN102372780A (zh) * 2010-08-23 2012-03-14 上海市计划生育科学研究所 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用
EP2718457A4 (en) 2011-06-06 2014-12-24 Immungene Inc GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
AU2013211059B8 (en) 2012-01-20 2017-12-21 Centre Hospitalier Regional Universitaire De Montpellier Targeted mutant alpha-helical bundle cytokines
CA2866126A1 (en) 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules
UA125637C2 (uk) * 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b

Similar Documents

Publication Publication Date Title
Reber et al. Targeting mast cells in inflammatory diseases
Lichtenberg Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000–2009
Chyi et al. The effects of tuition reforms on school enrollment in rural China
Weitzenfeld et al. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer
JP2016529232A5 (enExample)
Koelink et al. Targeting chemokine receptors in chronic inflammatory diseases: an extensive review
Fedderke et al. Does massive funding support of researchers work?: Evaluating the impact of the South African research chair funding initiative
JP2016527221A5 (enExample)
ES2657060T3 (es) Fusoquinas que implican citoquinas con afinidades de unión por el receptor fuertemente reducidas
EA201791137A1 (ru) Новые замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
WO2018102787A9 (en) Methods for determining car-t cells dosing
JP2017206548A5 (enExample)
WO2015160928A3 (en) Isolated t cell receptors and methods of use therefor
EP3243830A4 (en) Protein associated with disease resistance and encoding gene thereof, and use thereof in regulation of plant disease resistance
WO2016081885A3 (en) Panel-based genetic diagnostic testing for inherited eye diseases
EP3875470A4 (en) CHIMERIC ANTIGEN WITH ENHANCED MULTI-IMMUNE FUNCTION BY SPECIFIC BINDING TO A TARGET CELL, AND USE THEREOF
Whistler Patwin folk-taxonomic structures
JP2015210343A5 (enExample)
HRP20251546T1 (hr) Elastični i klizni valvularni spoj, pogodan za rad u prethodno napunjenim špricama i navedene šprice
Starzyńska et al. III ogólnopolska konferencja naukowa „Zarządzanie współczesnymi przedsiębiorstwami. Współczesne problemy gospodarcze w oczach młodego pokolenia”: Third National Scientific Conference „Managing today's enterprises. Contemporary economic problems in the eyes of the young generation”
JP2016113832A5 (enExample)
Kellogg Photographs-Travels-Africa, 1925-1926
Mitra Criminology-Crime and Correctional Administration
Rolland Mahatma Gandhi by Romain Rolland
王桂云 Lesson14 would you like some soup?